89 results
8-K
EX-1.1
GRTS
Gritstone Bio Inc
2 Apr 24
Entry into a Material Definitive Agreement
5:23pm
) in such proportion as is appropriate to reflect the relative benefits received by the Company on the one hand and the Underwriters on the other from the offering … such relative benefits but also the relative fault of the Company on the one hand and the Underwriters on the other in connection with the statements
424B5
GRTS
Gritstone Bio Inc
2 Apr 24
Prospectus supplement for primary offering
5:20pm
cytotoxic CD8+ T cell subclass, has the potential to drive transformational therapeutic and prophylactic benefits.
In oncology, we develop vaccines … that the benefits of increased protection of our potential ability to negotiate with the proponent of an unfriendly or unsolicited proposal to acquire or restructure
424B5
GRTS
Gritstone Bio Inc
1 Apr 24
Prospectus supplement for primary offering
4:43pm
CD8+ T cell subclass, has the potential to drive transformational therapeutic and prophylactic benefits.
In oncology, we develop vaccines that aim … seeking to acquire control of us to first negotiate with our board of directors. We believe that the benefits of increased protection of our potential
8-K
EX-99.1
o325fflrttx
8 Nov 23
Gritstone bio Reports Third Quarter 2023 Financial Results and Provides Corporate Updates
4:06pm
8-K
EX-99.1
ucj4rdqvds05um
27 Sep 23
Entry into a Material Definitive Agreement
4:07pm
8-K
EX-10.1
l2p2p9h7
6 Apr 23
Entry into a Material Definitive Agreement
4:38pm
424B3
bz3ixrahivo
14 Dec 22
Prospectus supplement
5:09pm